Consequently, more effective cancer therapy may be achieved by dual targeting of the LGR5- and LGR5+ cell populations to address both the LGR5- tumor bulk and initial metastatic seeding, and the LGR5+ cells that drive the growth of primary cancers and metastases. This evidence concerns the gene LGR5 and neoplasm.